Lakefront Biotherapeutics (LKFT) Capital Expenditures Growth (1y) (2015 - 2026)
Lakefront Biotherapeutics (LKFT) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 143.40% |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.54 Bn | 1.91 Mn | 97.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.59% |
| Dec 31, 2025 | -7.91% |
| Sep 30, 2025 | 32.75% |
| Jun 30, 2025 | -25.15% |
| Mar 31, 2025 | -36.16% |
| Dec 31, 2024 | -5.91% |
| Mar 31, 2024 | 12.24% |
| Dec 31, 2023 | -36.90% |
| Mar 31, 2023 | 53.54% |
| Jun 30, 2020 | -116.42% |
| Mar 31, 2020 | -36.28% |
| Dec 31, 2019 | 171.02% |
| Sep 30, 2019 | -671.48% |
| Jun 30, 2019 | -27.57% |
| Mar 31, 2019 | -39.11% |
| Dec 31, 2018 | 1,361.15% |
| Sep 30, 2018 | -100.06% |
| Jun 30, 2018 | 99.92% |
| Mar 31, 2018 | -30.13% |
| Jun 30, 2017 | -125,057.01% |